Anixa Biosciences Inc Quarterly Cash, Cash Equivalents, and Short-term Investments in USD from Q3 2011 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.
Summary
Anixa Biosciences Inc quarterly Cash, Cash Equivalents, and Short-term Investments history and growth rate from Q3 2011 to Q2 2024.
  • Anixa Biosciences Inc Cash, Cash Equivalents, and Short-term Investments for the quarter ending July 31, 2024 was $20.7M.
Cash, Cash Equivalents, and Short-term Investments, Quarterly (USD)
Cash, Cash Equivalents, and Short-term Investments, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $20.7M Jul 31, 2024 10-Q 2024-09-06
Q3 2023 $23.8M Oct 31, 2023 10-Q 2024-09-06
Q4 2018 $5.9M +$406K +7.39% Jan 31, 2019 10-Q 2019-03-13
Q3 2018 $5.06M -$1.78M -26.1% Oct 31, 2018 10-Q 2019-03-13
Q2 2018 $5.34M -$744K -12.2% Jul 31, 2018 10-Q 2018-09-07
Q1 2018 $5.42M +$295K +5.75% Apr 30, 2018 10-Q 2018-06-11
Q4 2017 $5.5M +$3.5M +175% Jan 31, 2018 10-Q 2018-03-09
Q3 2017 $6.84M +$3.6M +111% Oct 31, 2017 10-K 2019-01-11
Q2 2017 $6.09M +$2.14M +54.1% Jul 31, 2017 10-Q 2017-09-08
Q1 2017 $5.13M +$365K +7.67% Apr 30, 2017 10-Q 2017-05-26
Q4 2016 $2M -$4.13M -67.4% Jan 31, 2017 10-Q 2017-03-16
Q3 2016 $3.24M -$3.53M -52.2% Oct 31, 2016 10-K 2018-01-09
Q2 2016 $3.95M -$3.61M -47.8% Jul 31, 2016 10-Q 2016-08-19
Q1 2016 $4.76M -$3.72M -43.8% Apr 30, 2016 10-Q 2016-05-20
Q4 2015 $6.13M Jan 31, 2016 10-Q 2016-02-19
Q3 2015 $6.77M +$908K +15.5% Oct 31, 2015 10-K/A 2016-12-08
Q2 2015 $7.56M +$1.36M +21.9% Jul 31, 2015 10-Q 2015-08-18
Q1 2015 $8.48M +$6.71M +379% Apr 30, 2015 10-Q 2015-05-22
Q3 2014 $5.86M +$4.96M +553% Oct 31, 2014 10-K 2015-12-23
Q2 2014 $6.2M +$5.22M +532% Jul 31, 2014 10-Q 2014-09-15
Q1 2014 $1.77M +$496K +38.9% Apr 30, 2014 10-Q 2014-06-16
Q4 2013 $898K -$815K -47.6% Nov 30, 2013 10-Q 2014-09-15
Q3 2013 $898K +$58K +6.91% Oct 31, 2013 10-K 2015-01-29
Q2 2013 $982K +$142K +16.9% Jul 31, 2013 10-Q/A 2013-09-20
Q1 2013 $1.27M Apr 30, 2013 10-Q/A 2013-06-19
Q4 2012 $1.71M Jan 31, 2013 10-Q/A 2013-03-25
Q3 2012 $840K -$2.18M -72.2% Oct 31, 2012 10-K/A 2014-01-17
Q2 2012 $840K Jul 31, 2012 10-Q/A 2013-09-20
Q3 2011 $3.02M Oct 31, 2011 10-K 2013-01-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.